DVAX


William Blair Maintains Outperform On Dynavax Following Initiation Of Phase I/II Study In B-cell Lymphoma

In a research report issued today, William Blair analyst Katherine Xu maintained an Outperform rating on Dynavax Tech. (NASDAQ:DVAX) with a $4 price …

William Blair Reiterates Outperform On Dynavax Following Completion Of Enrollment In HBV-23

In a research report issued today, William Blair analyst Y Katherine Xu reiterated an Outperform rating on Dynavax Technologies (NASDAQ:DVAX) with a $4 price …

William Blair Reiterates Outperform Rating For Dynavax

In a research note released this morning, William Blair reiterated coverage on Dynavax Technologies Corporation (DVAX) with an Outperform rating and a price target of …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts